OXi4503

DRUG2 trials

Sponsors

Mateon Therapeutics, University of Florida

Conditions

Leukemia, Myelogenous, AcuteMyelodysplastic SyndromesSolid Tumors

Phase 1

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

CompletedNCT00977210

Mateon TherapeuticsSolid Tumors

Start: 2005-07-31Target: 40Updated: 2011-10-31

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

TerminatedNCT01085656

University of FloridaLeukemia, Myelogenous, Acute, Myelodysplastic Syndromes

Start: 2011-02-28End: 2016-01-31Updated: 2017-08-08

Related Papers

The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS

Blood2015-12-036 citations

Abstract P112: Mechanism of the Blood Pressure Response to a Novel Vascular Disrupting Combretastatin A1-Diphosphate (OXi4503)

Hypertension2015-09-01

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Blood2014-12-06

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Blood2013-11-1512 citations